Compare MGM Resorts International (MGM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs Merck & Co., Inc. — how do they compare? MGM Resorts International trades at $43.99 (market cap $11.10B), while Merck & Co., Inc. trades at $131.55 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 29× MGM Resorts International's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| MGM | MRK | |
|---|---|---|
Market Cap | $11.10B | $321.77B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $131.84 |
52-Week Low | $30.72 | $77.60 |
Enterprise Value | $38.40B | $368.53B |
Dividend Yield | 0.03% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $43.36, down 2.5% with bearish technical signals despite mixed earnings performance. The company reported record Q2 2026 revenue of $17.54B but missed EPS estimates, while analyst consensus remains divided with a $51.14 price target. Recent news highlights ongoing acquisition investigations and BetMGM's expansion in Canadian markets.
MGM faces near-term pressure from earnings volatility and acquisition uncertainty, but maintains strong revenue growth and digital expansion. Key risks include regulatory scrutiny and competitive pressures, while institutional sentiment leans neutral with balanced buy/hold ratings suggesting cautious optimism for recovery.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
